PharmaCann Inc.☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

PharmaCann Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

PharmaCann Inc. is one of 227 Biotech / Pharma companies tracked from CHICAGO. By capital raised it ranks among the largest (ahead of 100% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Series D+ — a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 100% of sector peers (real $). Modeled value above 87% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #6 of 7.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Series B$20.0M2014-09-18
   • First recorded raise — entered as Series B.
   • 1 investor on this round.
2. Series B$25.0M2015-06-01
   • Came back fast: 8 mo vs the ~15 mo sector norm.
   • Round roughly the size of the prior one.
   • 6 investors on this round.
3. Series B$23.8M2016-05-09
   • Raised 11 mo later, in step with the ~15 mo sector norm.
   • Round roughly the size of the prior one.
   • 6 investors on this round.
4. Series B$550K2017-07-01
   • Raised 14 mo later, in step with the ~15 mo sector norm.
   • Round 43.2× smaller than the prior — bridge or down round.
   • Switched to Rule 504 (was Rule 506(b)).
5. Series B$22.0M2018-06-15
   • Raised 11 mo later, in step with the ~15 mo sector norm.
   • Round 39.9× larger than the prior — scaling up.
   • Switched to Rule 506(b) (was Rule 504).
   • 22 investors on this round.
6. Series B$19.6M2020-02-02
   • Raised 20 mo later, in step with the ~15 mo sector norm.
   • Round roughly the size of the prior one.
   • 75 investors on this round.
7. Series B$27.7M2020-05-14
   • Came back fast: 3 mo vs the ~15 mo sector norm.
   • Round 1.4× larger than the prior — scaling up.
   • 1 investor on this round.
8. Series B$35.9M2020-09-10
   • Came back fast: 4 mo vs the ~15 mo sector norm.
   • Round roughly the size of the prior one.
   • 134 investors on this round.
9. Pre-Seed$475K2020-09-10
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 75.7× smaller than the prior — bridge or down round.
   • 4 investors on this round.
10. Series B$31.9M2021-03-05
    • Came back fast: 6 mo vs the ~15 mo sector norm.
    • Round 67.1× larger than the prior — scaling up.
    • 2 investors on this round.
11. Series D+$110.4M2021-06-14
    • Came back fast: 3 mo vs the ~15 mo sector norm.
    • Round 3.5× larger than the prior — scaling up.
    • 1 investor on this round.
12. Series D+$85.0M2021-06-24
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 9 investors on this round.
13. Series D+$25.0M2022-06-30
    • Raised 12 mo later, in step with the ~15 mo sector norm.
    • Round 3.4× smaller than the prior — bridge or down round.
    • 3 investors on this round.
14. Series D+$2.2M2022-10-31
    • Came back fast: 4 mo vs the ~15 mo sector norm.
    • Round 11.4× smaller than the prior — bridge or down round.
    • 11 investors on this round.
15. Series A$9.0M2023-04-03
    • Came back fast: 5 mo vs the ~15 mo sector norm.
    • Round 4.1× larger than the prior — scaling up.
    • 6 investors on this round.
16. Series D+$12.9M2023-04-03
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× larger than the prior — scaling up.
    • 6 investors on this round.
17. Series D+$7.0M2023-04-27
    • Came back fast: 1 mo vs the ~15 mo sector norm.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 1 investor on this round.
18. Series D+$10.0M2023-11-06
    • Came back fast: 6 mo vs the ~15 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • 1 investor on this round.
19. Series D+$5.0M2023-11-07
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 3 investors on this round.
20. Series D+$10.0M2023-12-01
    • Came back fast: 1 mo vs the ~15 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 1 investor on this round.
21. Series D+$35.0M2024-03-28
    • Came back fast: 4 mo vs the ~15 mo sector norm.
    • Round 3.5× larger than the prior — scaling up.
    • 7 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PharmaCann Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where PharmaCann Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at PharmaCann Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.